Abstract
Human norovirus is the leading cause of viral gastroenteritis, yet effective vaccines and therapeutics remain elusive. Using murine norovirus as a model, we found that mucosal immunoglobulin A (IgA) is both necessary and sufficient for protection against infection, whereas CD8 + T cells are dispensable. Robust intestinal IgA production requires at least 4 weeks of enteric infection, consistent with kinetics of human norovirus RNA clearance. Systemic vaccination elicits high titers of neutralizing serum IgG but fails to prevent enteric norovirus infection, phenocopying a recent human norovirus vaccine failure. In contrast, prophylactic delivery of dimeric anti-norovirus IgA via mRNA lipid nanoparticles confers sterilizing immunity. Together, these findings define a critical role for mucosal IgA in norovirus protection and identify IgA-based treatments as a therapeutic approach for human norovirus.
Funding Information
  • National Institutes of Health (R01AI183155)
  • National Institutes of Health (R01AI148467)
  • National Institutes of Health (1DP2AI184637)
  • National Institutes of Health (R01AI168016)
  • National Institutes of Health (R37AR40072)
  • National Institutes of Health (R01AI168016)
  • National Institutes of Health (1R01AI189484-01)
  • National Institutes of Health (1R01AI189484-01)
  • Burroughs Wellcome Fund
  • Penn Measey Scholars in Molecular Medicine Fellowship
  • Cancer Research Institute (CRI4964)
  • Colton Center for Autoimmunity at Yale

This publication has 83 references indexed in Scilit: